Therapy Development

We help pharmaceutical and biotechnology companies make better decisions.

AIQ’s software technologies can help pharmaceutical companies to evaluate novel therapies faster and with fewer participants, reducing costs and expediting clinical trials.

Every Disease is Different.
Every Person is Different. Every Lesion is Different.

AIQ HAS IMAGING ANALYSIS SOLUTIONS

With the AIQ Collaborative Workflow, the steps are customizable to meet the specific requirements for clinical studies.


Upload Images
Identification
Quantification
Matching
Classification

Consistent and Comprehensive Assessment

Intra-patient heterogeneity of treatment response drives clinical outcomes1-5.

115 non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy imaged with FDG PET/CT at baseline and post-treatment.

Each bar on chart represents an individual patient showing how each of their lesions are responding to treatment. Each lesion is detected, quantified and categorized as new, progressing, stable, partially responding or completely responding.

* 1. Harmon et al., J Clin Oncol 2017, including unpublished supplemental data analysis; 2. Kyriakopoulos et al, J Clin Oncol 2020. 3. Perk et al., J Clin Oncol. 2022. 4. Liu et al., European Society for Medical Oncology (ESMO) Congress 2022. 5. Varghese et al., ESMO Congress 2022

Earlier Determination and Prediction of Treatment Toxicity

Slide
Automatic Organ Segmentation

Retrospective 57 patient Phase I/II study comparing AIQ technology to experienced reader for evaluating heterogeneous system amyloid build up in multiple organs.

“This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis.”

- Weisman et al., WMIC 2021

Click to View Full Poster
Slide
Assess Organ-Specific Toxicity: Immunotherapy Application

Retrospective study of 58 melanoma patients treated with ICI therapy evaluated in a partnership with University of Wisconsin Carbone Cancer Center.

Accurate quantification of changes in the lung could significantly predict which patients had pneumonitis prior to actual diagnosis with an AUC of 0.99.

Click to View Immunotherapy Application Note
Slide
Assess Organ-Specific Toxicity:
Theranostics Application

13 prostate cancer patients from a Phase I/II trial treated with 177 Lu-PSMA-617 and imaged pre- and post-treatment with 68Ga-PSMA11-PET.

Quantification of PSMA expression shows
1. Associations between PSMA PET SUV and response by both overall survival and PSA response
2. Associations between degree of PSMA PET SUV in PSMA-expressing non-tumor tissues and adverse events

Nauseef et al., American Society of American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) 2022.

Click to View Full Poster
previous arrow
next arrow

Optimize Clinical Trial Participant Selection for Prospective Studies

  • Identify participants with high heterogeneity of treatment responses
  • Predict optimal vs. suboptimal responders using AIQ Score
  • Re-randomize participants for alternative therapies
  • Create customized models to refine enrollment criteria
  • Evaluate participants level dosage effectiveness

A VALUED PARTNER FOR YOUR STUDIES

AIQ COLLABORATION

AIQ’s collaboration consists of a workflow that is simple and easy to implement without interruption for single and multi-site studies. We pride ourselves on building a partnership that upholds our company’s values and value proposition. We also partner with CROs to acquire imaging data.

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

This will close in 40 seconds

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.

This will close in 40 seconds

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September 2018. He has led AIQ through two rounds of equity financing, team construction, product commercialization, and international expansion. Before joining the AIQ team, Eric was President and CEO of Swallow Solutions LLC, a medical device start-up with both therapeutic devices and functional beverages for dysphagia patients. Before that, Eric was General Manager, Premium Anesthesia and Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a $220 million global business and a large team spread over three continents. He has also held a series of marketing and business development roles at Baxter Healthcare, including Director of Renal Products and Services for the Latin America region. Eric has a B.S. in Chemical Engineering from Rice University and both an MBA and Master of Engineering Management degrees from the Kellogg School of Business. He lives in Madison with his wife and two children.

This will close in 40 seconds

Information on this page is intended for research use only. Applications and/or claims listed are not currently cleared for use in treatment of patients.